Autonomix Medical’s (AMIX) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of Autonomix Medical (NASDAQ:AMIX) in a research note released on Friday morning,Weiss Ratings reports.

Several other analysts have also recently weighed in on the stock. Zacks Research cut shares of Autonomix Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 28th. Wall Street Zen raised shares of Autonomix Medical to a “sell” rating in a research note on Saturday, July 26th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $5.00.

Autonomix Medical Price Performance

Shares of Autonomix Medical stock opened at $1.12 on Friday. Autonomix Medical has a twelve month low of $0.96 and a twelve month high of $21.49. The stock has a market cap of $6.93 million, a price-to-earnings ratio of -0.20 and a beta of -2.80. The company’s fifty day moving average is $1.12 and its 200 day moving average is $1.42.

Autonomix Medical (NASDAQ:AMIX) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.09). As a group, equities analysts anticipate that Autonomix Medical will post -10 earnings per share for the current fiscal year.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.